NICE recommends mirikizumab as a treatment option for Crohn's disease

The National Institute for Health and Care Excellence (NICE) has recommended interleukin-23 (IL-23) inhibitor mirikizumab (Omvoh; Eli Lilly) for the treatment of moderately to severely active Crohn’s disease. Final draft guidance published on 30 May 2025 said that mirikizumab can be offered on the NHS to people in England with Crohn’s disease where the condition […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.360489
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends mirikizumab as a treatment option for Crohn's disease

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Inflammatory Bowel Disease

article

NICE recommends mirikizumab as a treatment option for Crohn's disease

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 85%

Inflammatory Bowel Disease

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends mirikizumab as a treatment option for Crohn's disease · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS